TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
PRTA

Prothena Corporation plc

Healthcare · Biotechnology

8.30$ -4.1% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet PRTA
Line item 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – +9.6% +3,473.3% +41.1% +66.7% +26.7% +19.4% +7.9% +0.5% -15.9% -20.6% +83.0% +24.4% -8.1% -21.4% -40.3%
– – – +101,384.7% +41.6% +67.9% +26.1% +3.7% +8.9% +1.2% -12.3% -20.9% +95.4% +23.0% -11.1% -24.1% -35.1%
– – – – +41.5% +66.2% +26.2% +4.4% +7.9% +2.4% -12.1% -21.4% +96.1% +22.7% -12.9% -23.8% -34.8%
– – – – +41.5% +66.2% +26.2% +4.4% +7.9% +2.4% -12.1% -21.4% +96.1% +22.7% -12.9% -23.8% -34.8%
– – – – -74.0% +2,932.8% -71.1% -65.0% +34.8% -99.2% +3,300.0% -77.9% -13.3% +376.9% +8,221.0% -100.0% –
– – – – – – – – – – -6,800,100.0% – -101.0% – – – –
– – +4.2% +35.7% -0.6% -7.4% +23.7% +1,361.7% -2.6% -3.9% -92.7% -34.2% -21.1% +298.0% – – –
– – – – – – – – – – – – – – – – –
– – – -30.0% -100.0% – – – – – – – – – – – –
– – +214.2% -72.2% +226.5% +55.7% +72.7% +285.0% -5.7% +97.2% -16.8% +1.8% -3.8% -5.1% -0.7% -55.4% -23.0%
– – +366.9% -79.2% +324.7% +62.6% +84.5% +84.9% -9.0% -60.1% +18.7% +45.9% +29.4% +49.9% +13.4% -14.7% -15.8%
– – – – – +0.0% +0.0% +0.6% -98.6% +124.4% +210.1% +8.1% +7.8% +9.0% -82.8% +134.3% +10.6%
– – +280.0% – – +163.8% -4.3% +189.2% +4.3% -89.2% -15.5% +231.5% -10.3% +151.2% +173.9% -69.4% -24.4%
– – – – – – – – -8.4% – – – – – – – –
– – -6,536.0% – +37.0% +67.3% +24.4% +1.3% +11.4% -20.7% -15.5% -32.6% +153.3% +33.5% -9.8% -13.3% -42.4%
– – – – – – – – – – – – – – – – –
– +26.3% +0.0% -17.5% +27.6% +32.5% +22.9% +13.3% +9.6% +5.1% +0.8% +0.1% +21.4% -2.3% +12.3% +1.0% +0.1%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?